WEKO3
アイテム
Carbon ion radiotherapy for sacral chordoma
https://repo.qst.go.jp/records/62857
https://repo.qst.go.jp/records/6285785148d74-3090-48e5-ab74-4bd8f859eae4
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2008-11-19 | |||||
| タイトル | ||||||
| タイトル | Carbon ion radiotherapy for sacral chordoma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kamada, Tadashi
× Kamada, Tadashi× Imai, Reiko× Tsuji, Hiroshi× Serizawa, Itsuko× Okada, Toru× 鎌田 正× 今井 礼子× 辻 比呂志× 芹澤 慈子× 岡田 徹 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objectives: To evaluate the effectiveness and safety of carbon ion radiotherapy in patients with sacral chorodma and to compare the results of carbon ion radiotherapy with those of surgical series in literature. Methods: Between 1996 and 2007, 95 patients with sacral chordoma were included in the phase I/II and phase II study of carbon ion radiotherapy for unresectable bone and soft tissue sarcomas. There were sixty-eight males and 27 females. Median age was 66 years (30-85). Eighty-four patients were presented with primary disease and 11 patients with post operative recurrent tumor. Total dose of52.8 to 73.6 GyE was given in 16 fractions over 4 weeks (4 days a week). Results: All patients completed the planned carbon ion radiotherapy. Median survival time was 42 months (13-112). Overall survival rate at 5 years (86%) in patients with sacral chordoma treated by carbon ion radiotherapy is similar to those in reported data on patients treated by surgical resection with/without adjuvant radiotherapy. Local control rate at 5years (88%) in patients with sacral chordoma treated by carbon ion radiotherapy is better than those in reported data. Median time local failure was 35 months (13-60). Four patients treated with a total dose of 73.6 GyE experienced Grade 3/4 skin/soft tissue complications. No other treatment-related surgical interventions including colostomy or urinary diversion were carried out in this series. Fifteen patients required persistent medication for peripheral neuropathy. Conclusions: Carbon ion therapy is suggested to be an effective and safe treatment for sacral chordomas, but further experience and longer follow-up are still needed. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 14th Annual CTOS Meeting | |||||
| 発表年月日 | ||||||
| 日付 | 2008-11-15 | |||||
| 日付タイプ | Issued | |||||
